Mar 1
Biotech investment banking: the complete guide for 2026
Outlook / 2026
12 min
Hong Kong (HQ)ShanghaiZurichChicago
HKG time - 14:32 HKTEN/ZHLinkedIncontact@visionlifesciences.com
Biotech Consulting - Cross-Border Pharma Advisory
Biotech Consulting & Cross-Border Pharma Advisory.
Life science consulting for licensing, M&A, partnerships, and deal-making across global pharma and biotech.
Partner-led engagementsNDA-first conversationsResponse within 24 hours
NetworkTri-ContinentalAsia · Europe · USA
Cross-Border DealsHundreds FacilitatedLicensing · Partnerships · M&A
Combined ExperienceDecadesPharma & biotech business development
Transaction OpportunityBillionsSourced and evaluated
House view
The next decade of medicine will be written by partnerships that move across borders — not within them.
From the firmVision Lifesciences
Services
Strategic advisory across the full deal lifecycle.
Each engagement is led by senior advisors with first-hand operating experience across our three core regions. We work selectively, with a focused team, and stay involved from sourcing through close.
/ 01
In-Licensing
Acquire rights to innovative therapeutics and technologies from global sources.
- Asset sourcing
- Scientific diligence
- Deal execution
/ 02
Out-Licensing
Represent differentiated programs to qualified strategic buyers and partners.
- Buyer mapping
- Package preparation
- Terms negotiation
/ 03
Strategic Partnerships
Build alliances for development, manufacturing, and commercialization.
- Co-development
- Cross-border manufacturing
- Joint commercialization
/ 04
NewCo Formation
Spin assets into independent entities with global capital and dedicated focus.
- Carve-out structuring
- Capital syndication
- Governance design
Therapeutic focus
Where our network runs deepest.
We advise across modalities and indications. These are the areas where our cross-border relationships, scientific depth, and recent deal flow are most concentrated.
/ 01
Oncology
ADCs, bispecifics, targeted small molecules, and novel modalities.View →/ 02
Immunology
Autoimmune, inflammation, and next-generation immunomodulators.View →/ 03
Metabolic
GLP-1 combinations, NASH, and emerging cardiometabolic.View →/ 04
Cell & Gene
CAR-T, allogeneic platforms, and gene therapy technologies.View →/ 05
CNS
Neurodegeneration, psychiatry, and rare neurological indications.View →/ 06
Rare Disease
Orphan therapeutics and ultra-rare development programs.View →/ 07
Devices & Dx
Medical devices, diagnostics, and companion diagnostics.View →/ 08
Digital Health
AI-led discovery, trial tech, and digital therapeutic platforms.View →Why Vision Lifesciences
A specialist advisor for life-science deal-making.
Decades of combined experience in pharma and biotech business development. Our specialized knowledge and tri-continental network make us the catalyst for life-changing collaborations.
01
Global Network
Direct relationships with biotechs, academic institutions, and pharma across Asia, Europe, and the USA.
02
Asset Expertise
Deep scientific, commercial, regulatory, and IP evaluation across modalities and indications.
03
Deal Experience
Hundreds of cross-border life-science deals facilitated across licensing, partnerships, and NewCos.
04
End-to-End Support
From opportunity sourcing and diligence through negotiation, signing, and integration.
Footprint · 04 / 04Live · synced UTC
Hong KongHKGHeadquarters · Asia14:32HKT · UTC +08
ShanghaiPVGGreater China desk14:32CST · UTC +08
ZurichZRHEU & UK desk08:32CET · UTC +01
ChicagoORDAmericas desk01:32CDT · UTC −05
Coverage · 24hOne integrated team across three continents.
What we do across the corridor
Scope of engagement.
The mandates we run, the deal sizes we work, and the speed at which a partner-led team can move.
ServicesLicensing · M&A · Partnerships · NewCoBuy-side and sell-side, end to end.
Therapeutic areasOncology · Immunology · Metabolic · CNS · RareModality-agnostic — small molecule to cell & gene.
Deal size$25M – $1B+ in committed economicsBespoke structures, not a fee table.
Typical timeline4 – 9 months · term-sheet to closePartner-led from first call through close.
Engagements are partner-led · NDA-firstDiscuss a mandate →
Latest insights
Selected thinking from the desk.
Featured · Geography
China clinical trials: cost, speed, and regulatory advantages
Run clinical trials in China and save 60% on costs with 2–5× faster enrollment. NMPA IND process, MRCT strategy for FDA acceptance, BIOSECURE Act clarification, and the China CRO landscape.
Continue reading →Feb 28
NMPA drug approval process: complete guide 2026
Regulatory
11 min
Feb 14
Dragon Pipeline / February - top deals from Asia this month
Newsletter
6 min
Jan 30
Capital access for biotech: routes to global syndicate
Capital
8 min
Jan 18
BioDeal Weekly / January wrap - out-licensing trends
Newsletter
5 min
Jan 09
Cross-border partnerships: the Asia to US corridor in 2026
Strategy
10 min
Newsletters
Pharma deal intelligence, delivered.
Dragon PipelineMONTHLY
The Asia → world deal feed.
Curated cross-border licensing, M&A, and partnership intelligence from Greater China, the corridor that's reshaping global pharma.
BioDeal WeeklyWEEKLY
Every cross-border deal that mattered, in five minutes.
A Friday digest of the week's biggest licensing, M&A, and capital movements across pharma and biotech worldwide.
Engagement
Begin a confidential conversation.
Contact us ->RESPONSE WITHIN 24 HOURS